Pfizer is taking the ax to its preclinical R&D group for biosimilars in a move designed to end — at least for now — any new expansion of the pipeline for knockoffs.
After messages began to pop up on social media from staffers getting the ax, a Pfizer spokesperson confirmed to me that the company is cutting 150 staffers at 2 sites, in Lake Forest, IL and Chennai, India and ending development of 5 preclinical programs.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription